SpineGuard announced the authorization under 510K #220160 by the FDA (Food and Drug Administration) to commercialize in the United States its Threaded PediGuard device for anterior approach instrumented spine surgery.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2335 EUR | +2.19% | +5.66% | +16.98% |
Apr. 17 | SpineGuard SA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
2023 | SpineGuard SA announced that it expects to receive ?1.998 million in funding | CI |
1st Jan change | Capi. | |
---|---|---|
+16.98% | 11.69M | |
+73.50% | 12.41B | |
-19.26% | 8.14B | |
+2.40% | 7.2B | |
+3.66% | 5.93B | |
+11.89% | 5.43B | |
+37.45% | 4.89B | |
-19.94% | 4.09B | |
-35.58% | 2.49B | |
+0.74% | 2.04B |
- Stock Market
- Equities
- ALSGD Stock
- News SpineGuard
- SpineGuard Obtains FDA Clearance for Commercial Release of Its “Threaded Pediguard” in Anterior Approach Spine Surgery